B O O K - American College of Rheumatology

wednesday
100
9:30 am
2081. Rheuma on the Road – The Rheuma Truck Mass
Communication, Educational Advertising and Creative
Community Care.
Matthias K. Schneider 2 and Martina Blumenroth 1 , 1 Cooperative
Rheumatology Association Rhine-Ruhr MNR-Klinik, Duesseldorf,
Germany, 2 MNR-Klinik, Duesseldorf, Germany
9:45 am
2082. A Study of Pictorial Representation (Mind Map) To
Convey Health Education on Osteomalacia to People with Low
Language Literacy Skills.
Adewale O. Adebajo 5 , David Walker 3 , Sandra Robinson 4 ,
Yogenjagat Singh 3 , Philip Helliwell 2 and Anisur Rahman 1 ,
1
University College London, London, United Kingdome,
2
University of Leeds, Leeds, United Kingdom, 3 University
of Newcastle, Newcastle, United Kingdom, 4 University of
Newcastler, Newcastle, United Kingdom, 5 University of Sheffield
Medical School Sheffield United Kingdom, Sheffield, United
Kingdom
10:00 am
2083. Using Social Media To Recruit for a Translational Lupus
Research Study for the Millennial Generation – The SisSLE
Experience.
Marlene H. Kern 2 , Sally Kaplan 2 , Bonnie Gonzales 2 , Betty
Diamond 1 and Peter K. Gregersen 2 , 1 Feinstein Institute for
Medical Research, Manhasset, NY, 2 The Feinstein Institute for
Medical Research, Manhasset, NY
ARHP Concurrent Sessions
9:15 - 10:15 am
B309
Building Effective Teams: Recommended Leadership
Strategies cP PS
Moderator: Michael J. Jennings, RT, CBDT; Arthritis Care; Troy, NY
Speakers: Basia Belza, PhD, RN; University of Washington;
Seattle, WA
Marian T. Hannan, DSc, MPH; Hebrew Senior Life and Harvard
Medical School; Boston, MA
Maura D. Iversen, PT, DPT, SD, MPH; Northeastern University;
Boston, MA
Session Overview:
Regardless of work setting or discipline, working collaboratively
as a team enhances productivity, increases satisfaction, and
leads to improved outcomes.
Upon completion of this session, participants should be able to:
• compose clear objectives for team work and measurable
outcomes
• define the attributes of a successful team
• build and/or transform team culture and define the context of
group interaction
B308
Pain Management In the Age of Abuse and Litigation
c/r PS PM
Moderator: Kori A. Dewing, MN, ARNP; VA Mason Medical
Center; Everett, WA
Speaker: Allan Gibofsky, MD, JD; Hospital for Special Surgery;
New York, NY
2010 Program Book
Session Overview:
Efforts to identify pain management barriers and attempts to
modify those barriers through quality improvement programs
have increased dramatically within health care organizations
in recent years. National clinical practice guidelines for the
management of acute pain and cancer pain have been published
by numerous professional societies including the American Pain
Society and by the Agency for Health Care Policy and Research.
There is general agreement, however, that the implementation
of pain management strategies has proven problematic.
Research on barriers to effectively manage pain indicates that
problems fall into three main categories: those related to health
care professionals; those related to patients and families;
and, those related to health care systems. Thus, health care
professionals may under treat pain for several reasons, including
inadequate knowledge of pain management, inadequate
knowledge of the side effects of analgesics, poor assessment of
pain, and concern about regulation of controlled substances.
Despite efforts by organizations like Joint Commission on
Accreditation of Healthcare Organizations to identify pain as
“the fifth vital sign”, the health care system gives low priority
to (and low reimbursement for) effective pain management
strategies. This session will address strategies to effectively
manage musculoskeletal and inflammatory pain in the clinical
rheumatology setting and identify strategies to reduce the
likelihood of litigation and administrative sanction related to use
of controlled substances.
Upon completion of this session, participants should be able to:
• describe the incidence of prescription drug abuse in
rheumatology
• design strategies to reduce prescription drug abuse in a
rheumatology practice
• describe best practice strategies to protect against litigation
related to prescription medication abuse
B402
Rheumatic Disease Update: Juvenile Idiopathic
Arthritis P/C
Moderator: Karen L. Kerr, MSN, NP, CPNP, PNP; Children’s
Hospital of Michigan; Detroit, MI
Speaker: Helen M. Emery, MD; Children’s Hospital & Regional
Medicine; Seattle, WA
Session Overview:
Juvenile idiopathic arthritis remains the most common
musculoskeletal problem in children below the age of 16 years.
Many patients show frequent flares or persistent disease activity
with significant morbidity and serious complications. Recent
investigations in the pathophysiology of juvenile idiopathic
arthritis have focused on mediators of the innate immune
system and IL-1beta, IL-6 and IL-18 as well as phagocyte-specific
S100-proteins are correlated with disease activity and secondary
complications. These insights have lead to new promising
treatment approaches, like application of recombinant anti-IL-1
receptor antagonist or anti-IL-6 receptor antibodies in patients
resistant to conventional anti-inflammatory treatment. With
these new discoveries, rheumatology professionals need to keep
up with the pathophysiology and novel treatment options of
juvenile idiopathic arthritis.
Upon completion of this session, participants should be able to:
• discuss the pathophysiology of systemic onset juvenile
idiopathic arthritis